Article: Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright

Article - Media

Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright

TheFly, 10 January 2020

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $1.20 price target on Ekso Bionics, saying the pre-announced “record” fourth quarter “bodes well” for continued growth in 2020.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.

 

RELATED:

Article: Ekso Bionics Announces Closing of $5.0 Million Registered Direct Offering

Article - Media

Ekso Bionics Announces Closing of $5.0 Million Registered Direct Offering

GlobeNewswire, 20 December 2019

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced registered direct offering of 11,111,116 shares of its common stock and warrants to purchase up to 8,333,337 shares of its common stock, at a combined purchase price of $0.45 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.
RELATED:

Article: H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO)

Article - Media

H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO)

Catie Powers

Markets.co, 31 October 2019

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a rating on EKSO BIONICS ( – Research Report) today and set a price target of $1.20. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.48.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.
RELATED:

Article: H.C. Wainwright Starts Ekso Bionics (EKSO) at Buy

Article - Media

H.C. Wainwright Starts Ekso Bionics (EKSO) at Buy

StreetInsider.com, 28 October 2019

H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on Ekso Bionics (NASDAQ: EKSO) with a Buy rating and a price target of $1.20.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.

RELATED:

Article: H.C. Wainwright Initiates Coverage On Ekso Bionics Holdings with Buy Rating, Announces $1.2 Price Target

Article - Media

H.C. Wainwright Initiates Coverage On Ekso Bionics Holdings with Buy Rating, Announces $1.2 Price Target

Benzinga, 1 October 2019

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.

RELATED:

Article: How to Handle a Short Attack on a Stock You Own

Article - Media

How to Handle a Short Attack on a Stock You Own

Keith Fitz-Gerald

TotalWealth, 3 June2015

An anonymous individual writing under the name “The Pump Stopper” launched a vicious attack on Ekso Bionics Holdings Inc. (OTC:EKSO) yesterday that immediately pressured the stock and caused it to drop 24.28% to close at $1.36 a share on heavy volume. Understandably, that makes a lot of people nervous.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.